Voyageur Pharmaceuticals Ltd.
VM.V
TSX
| 02/28/2025 | 11/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 61.11% | 26.84% | |||
| Depreciation & Amortization | -33.33% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 61.02% | 26.81% | |||
| Operating Income | -61.02% | -26.81% | |||
| Income Before Tax | -71.41% | -27.12% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -71.41% | -27.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -71.41% | -27.12% | |||
| EBIT | -61.02% | -26.81% | |||
| EBITDA | -61.11% | -26.84% | |||
| EPS Basic | -54.17% | -26.32% | |||
| Normalized Basic EPS | -53.33% | -25.00% | |||
| EPS Diluted | -54.17% | -26.32% | |||
| Normalized Diluted EPS | -53.33% | -25.00% | |||
| Average Basic Shares Outstanding | 11.57% | -0.04% | |||
| Average Diluted Shares Outstanding | 11.57% | -0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||